Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.86
+0.12 (0.81%)
Sep 30, 2026, 4:08 PM HKT

Sinopharm Group Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Sinopharm Group stock has a consensus rating of "Buy" and an average price target of $21.10. The average 1-year stock price forecast is 41.99% higher than the current stock price, while the lowest is $17.04 (+14.67%) and the highest is $27.75 (+86.74%).

Price Target: $21.10 (+41.99%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$17.04$21.10$21.05$27.75
Change+14.67%+41.99%+41.66%+86.74%
* Price targets were last updated on Aug 26, 2026.

Analyst Ratings

The average analyst rating for Sinopharm Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26Jul '26Aug '26Sep '26
Strong Buy566777
Buy444333
Hold543455
Sell000000
Strong Sell000000
Total141413141515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$24.70
BuyMaintains$24.70+66.22%Aug 26, 2026
Unknown Analyst
CLSA
No rating
CLSA
Buy
Maintains
$21.10
BuyMaintains$21.10+41.99%Aug 25, 2026
Unknown Analyst
Citi
No rating
Citi
Buy
Maintains
$22.60 → $20.40
BuyMaintains$22.60 → $20.40+37.28%Aug 25, 2026
Unknown Analyst
Citic Securities
No rating
Citic Securities
Buy
Maintains
$21.00
BuyMaintains$21.00+41.32%Jul 1, 2026
Unknown Analyst
Morgan Stanley
No rating
Morgan Stanley
Buy
Maintains
$23.00
BuyMaintains$23.00+54.78%May 14, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
582.69B
from 575.17B
Increased by 1.31%
Revenue Next Year
605.77B
from 582.69B
Increased by 3.96%
EPS This Year
2.37
from 2.29
Increased by 3.39%
EPS Next Year
2.55
from 2.37
Increased by 7.64%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
521.05B552.15B596.57B584.51B575.17B582.69B
Revenue Growth
14.16%5.97%8.05%-2.02%-1.60%1.31%
Gross Profit
44.05B47.43B48.51B44.26B41.67B41.34B
Gross Margin
8.45%8.59%8.13%7.57%7.25%7.10%
Operating Income
20.98B22.76B22.32B17.82B17.23B16.55B
Net Income
7.76B8.53B9.05B7.05B7.16B7.41B
EPS
----2.292.37
EPS Growth
----1.33%3.39%
Forward PE
4.936.055.827.016.855.36
Dividend / Share
0.750.820.870.680.690.71
Dividend Growth
8.70%9.33%6.10%-21.84%1.47%2.88%
Free Cash Flow
----12.22B24.01B
No. Analysts
-----14
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High603.6B
Avg582.7B
Low567.2B

Revenue Growth

Revenue Growth202620272028
High
4.9%
Avg
1.3%
Low
-1.4%

EPS Forecast

EPS202620272028
High2.89
Avg2.37
Low2.11

EPS Growth

EPS Growth202620272028
High
26.2%
Avg
3.4%
Low
-8.1%